TY  - JOUR
AU  - Ludwig, Gerd
AU  - Ranđelović, Ivan
AU  - Dimić, Dušan
AU  - Komazec, Teodora
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Rüffer, Tobias
AU  - Kaluđerović, Goran N.
PY  - 2024
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6642
AB  - The (pentamethylcyclopentadienyl)chloridoiridium(III) complex bearing a κP,κS-bonded Ph2PCH2CH2SPh ligand ([Ir(η5-C5Me5)Cl(Ph2P(CH2)2SPh-κP,κS)]PF6, (1)] was synthesized and characterized. Multinuclear (1H, 13C and 31P) NMR spectroscopy was employed for the determination of the structure. Moreover, SC-XRD confirmed the proposed structure belongs to the “piano stool” type. The Hirshfeld surface analysis outlined the most important intermolecular interactions in the structure. The crystallographic structure was optimized at the B3LYP-D3BJ/6-311++G(d,p)(H,C,P,S,Cl)/LanL2DZ(Ir) level of theory. The applicability of this level was verified through a comparison of experimental and theoretical bond lengths and angles, and 1H and 13C NMR chemical shifts. The Natural Bond Orbital theory was used to identify and quantify the intramolecular stabilization interactions, especially those between donor atoms and Ir(III) ions. Complex 1 was tested on antitumor activity against five human tumor cell lines: MCF-7 breast adenocarcinoma, SW480 colon adenocarcinoma, 518A2 melanoma, 8505C human thyroid carcinoma and A253 submandibular carcinoma. Complex 1 showed superior antitumor activity against cisplatin-resistant MCF-7, SW480 and 8505C cell lines. The mechanism of tumoricidal action on 8505C cells indicates the involvement of caspase-induced apoptosis, accompanied by a considerable reduction in ROS/RNS and proliferation potential of treated cells.
PB  - Basel: MDPI
T2  - Biomolecules
T1  - (Pentamethylcyclopentadienyl)chloridoiridium(III) Complex Bearing Bidentate Ph2PCH2CH2SPh-κP,κS Ligand
IS  - 4
VL  - 14
DO  - 10.3390/biom14040420
SP  - 420
ER  - 

@article{
author = "Ludwig, Gerd and Ranđelović, Ivan and Dimić, Dušan and Komazec, Teodora and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Rüffer, Tobias and Kaluđerović, Goran N.",
year = "2024",
abstract = "The (pentamethylcyclopentadienyl)chloridoiridium(III) complex bearing a κP,κS-bonded Ph2PCH2CH2SPh ligand ([Ir(η5-C5Me5)Cl(Ph2P(CH2)2SPh-κP,κS)]PF6, (1)] was synthesized and characterized. Multinuclear (1H, 13C and 31P) NMR spectroscopy was employed for the determination of the structure. Moreover, SC-XRD confirmed the proposed structure belongs to the “piano stool” type. The Hirshfeld surface analysis outlined the most important intermolecular interactions in the structure. The crystallographic structure was optimized at the B3LYP-D3BJ/6-311++G(d,p)(H,C,P,S,Cl)/LanL2DZ(Ir) level of theory. The applicability of this level was verified through a comparison of experimental and theoretical bond lengths and angles, and 1H and 13C NMR chemical shifts. The Natural Bond Orbital theory was used to identify and quantify the intramolecular stabilization interactions, especially those between donor atoms and Ir(III) ions. Complex 1 was tested on antitumor activity against five human tumor cell lines: MCF-7 breast adenocarcinoma, SW480 colon adenocarcinoma, 518A2 melanoma, 8505C human thyroid carcinoma and A253 submandibular carcinoma. Complex 1 showed superior antitumor activity against cisplatin-resistant MCF-7, SW480 and 8505C cell lines. The mechanism of tumoricidal action on 8505C cells indicates the involvement of caspase-induced apoptosis, accompanied by a considerable reduction in ROS/RNS and proliferation potential of treated cells.",
publisher = "Basel: MDPI",
journal = "Biomolecules",
title = "(Pentamethylcyclopentadienyl)chloridoiridium(III) Complex Bearing Bidentate Ph2PCH2CH2SPh-κP,κS Ligand",
number = "4",
volume = "14",
doi = "10.3390/biom14040420",
pages = "420"
}

Ludwig, G., Ranđelović, I., Dimić, D., Komazec, T., Maksimović-Ivanić, D., Mijatović, S., Rüffer, T.,& Kaluđerović, G. N.. (2024). (Pentamethylcyclopentadienyl)chloridoiridium(III) Complex Bearing Bidentate Ph2PCH2CH2SPh-κP,κS Ligand. in Biomolecules
Basel: MDPI., 14(4), 420.
https://doi.org/10.3390/biom14040420

Ludwig G, Ranđelović I, Dimić D, Komazec T, Maksimović-Ivanić D, Mijatović S, Rüffer T, Kaluđerović GN. (Pentamethylcyclopentadienyl)chloridoiridium(III) Complex Bearing Bidentate Ph2PCH2CH2SPh-κP,κS Ligand. in Biomolecules. 2024;14(4):420.
doi:10.3390/biom14040420 .

Ludwig, Gerd, Ranđelović, Ivan, Dimić, Dušan, Komazec, Teodora, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Rüffer, Tobias, Kaluđerović, Goran N., "(Pentamethylcyclopentadienyl)chloridoiridium(III) Complex Bearing Bidentate Ph2PCH2CH2SPh-κP,κS Ligand" in Biomolecules, 14, no. 4 (2024):420,
https://doi.org/10.3390/biom14040420 . .

TY  - JOUR
AU  - Arlt, Sören
AU  - Petković, Vladana
AU  - Ludwig, Gerd
AU  - Eichhorn, Thomas
AU  - Lang, Heinrich
AU  - Rüffer, Tobias
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Kaluđerović, Goran
PY  - 2021
UR  - https://www.mdpi.com/1420-3049/26/7/1860
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4220
AB  - Neutral [Ru(η6-arene)Cl2{Ph2P(CH2)3SPh-κP}] (arene = benzene, indane, 1,2,3,4-tetrahydronaphthalene: 2a, 2c and 2d) and cationic [Ru(η6-arene)Cl(Ph2P(CH2)3SPh-κP,κS)]X complexes (arene = mesitylene, 1,4-dihydronaphthalene; X = Cl: 3b, 3e; arene = benzene, mesitylene, indane, 1,2,3,4-tetrahydronaphthalene, and 1,4-dihydronaphthalene; X = PF6: 4a–4e) complexes were prepared and characterized by elemental analysis, IR, 1H, 13C and 31P NMR spectroscopy and also by single-crystal X-ray diffraction analyses. The stability of the complexes has been investigated in DMSO. Complexes have been assessed for their cytotoxic activity against 518A2, 8505C, A253, MCF-7 and SW480 cell lines. Generally, complexes exhibited activity in the lower micromolar range; moreover, they are found to be more active than cisplatin. For the most active ruthenium(II) complex, 4b, bearing mesitylene as ligand, the mechanism of action against 8505C cisplatin resistant cell line was determined. Complex 4b induced apoptosis accompanied by caspase activation.
PB  - MDPI
T2  - Molecules
T1  - Arene Ruthenium(II) Complexes Bearing the κ-P or κ-P,κ-S Ph2P(CH2)3SPh Ligand
IS  - 7
VL  - 26
DO  - 10.3390/molecules26071860
SP  - 1860
ER  - 

@article{
author = "Arlt, Sören and Petković, Vladana and Ludwig, Gerd and Eichhorn, Thomas and Lang, Heinrich and Rüffer, Tobias and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Kaluđerović, Goran",
year = "2021",
abstract = "Neutral [Ru(η6-arene)Cl2{Ph2P(CH2)3SPh-κP}] (arene = benzene, indane, 1,2,3,4-tetrahydronaphthalene: 2a, 2c and 2d) and cationic [Ru(η6-arene)Cl(Ph2P(CH2)3SPh-κP,κS)]X complexes (arene = mesitylene, 1,4-dihydronaphthalene; X = Cl: 3b, 3e; arene = benzene, mesitylene, indane, 1,2,3,4-tetrahydronaphthalene, and 1,4-dihydronaphthalene; X = PF6: 4a–4e) complexes were prepared and characterized by elemental analysis, IR, 1H, 13C and 31P NMR spectroscopy and also by single-crystal X-ray diffraction analyses. The stability of the complexes has been investigated in DMSO. Complexes have been assessed for their cytotoxic activity against 518A2, 8505C, A253, MCF-7 and SW480 cell lines. Generally, complexes exhibited activity in the lower micromolar range; moreover, they are found to be more active than cisplatin. For the most active ruthenium(II) complex, 4b, bearing mesitylene as ligand, the mechanism of action against 8505C cisplatin resistant cell line was determined. Complex 4b induced apoptosis accompanied by caspase activation.",
publisher = "MDPI",
journal = "Molecules",
title = "Arene Ruthenium(II) Complexes Bearing the κ-P or κ-P,κ-S Ph2P(CH2)3SPh Ligand",
number = "7",
volume = "26",
doi = "10.3390/molecules26071860",
pages = "1860"
}

Arlt, S., Petković, V., Ludwig, G., Eichhorn, T., Lang, H., Rüffer, T., Mijatović, S., Maksimović-Ivanić, D.,& Kaluđerović, G.. (2021). Arene Ruthenium(II) Complexes Bearing the κ-P or κ-P,κ-S Ph2P(CH2)3SPh Ligand. in Molecules
MDPI., 26(7), 1860.
https://doi.org/10.3390/molecules26071860

Arlt S, Petković V, Ludwig G, Eichhorn T, Lang H, Rüffer T, Mijatović S, Maksimović-Ivanić D, Kaluđerović G. Arene Ruthenium(II) Complexes Bearing the κ-P or κ-P,κ-S Ph2P(CH2)3SPh Ligand. in Molecules. 2021;26(7):1860.
doi:10.3390/molecules26071860 .

Arlt, Sören, Petković, Vladana, Ludwig, Gerd, Eichhorn, Thomas, Lang, Heinrich, Rüffer, Tobias, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Kaluđerović, Goran, "Arene Ruthenium(II) Complexes Bearing the κ-P or κ-P,κ-S Ph2P(CH2)3SPh Ligand" in Molecules, 26, no. 7 (2021):1860,
https://doi.org/10.3390/molecules26071860 . .

TY  - JOUR
AU  - Edeler, David
AU  - Arlt, Sören
AU  - Petković, Vladana
AU  - Ludwig, Gerd
AU  - Drača, Dijana
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Kaluđerović, Goran N.
PY  - 2018
UR  - http://linkinghub.elsevier.com/retrieve/pii/S0162013417306165
UR  - http://www.ncbi.nlm.nih.gov/pubmed/29288894
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2954
AB  - SBA-15 (Santa Barbara Amorphous 15) mesoporous silica and its functionalized form (with 3-mercaptopropyltriethoxysilane) SBA-15~SH were used as carriers for [Ru(η6-p-cymene)Cl2{Ph2P(CH2)3SPh-κP}] complex, denoted as [Ru]. Prepared mesoporous silica nanomaterials were characterized by traditional methods. Materials without [Ru] complex did not show any cytotoxic activity against melanoma B16 and B16-F10 cell lines. On the contrary, materials containing [Ru] such as SBA-15|[Ru] and SBA-15~SH|[Ru], exhibited very high activity against tested tumor cell lines, moreover with similar inhibitory potential. According to the loaded amount of the [Ru] in SBA-15|[Ru] and SBA-15~SH|[Ru] the IC50 values are 1-2μM depending on the test used, thus in comparison to [Ru] alone the activity of nanomaterials containing [Ru] are elevated 3-6 times in vitro. However, the mechanism of apoptosis induction differs for these two mesoporous silica. Unlike reference [Ru] compound and SBA-15~SH|[Ru], SBA-15|[Ru] induces high caspase activation. Discrepancy in mechanism of drugs action at intracellular level points towards an influence of functionalization as well as availability of the drug. Moreover, both SBA-15|[Ru] and SBA-15~SH|[Ru] similarly to [Ru] are declining autophagy in B16 cell line.
T2  - Journal of Inorganic Biochemistry
T1  - Delivery of [Ru(η6-p-cymene)Cl2{Ph2P(CH2)3SPh-κP}] using unfunctionalized and mercapto functionalized SBA-15 mesoporous silica: Preparation, characterization and in vitro study.
VL  - 180
DO  - 10.1016/j.jinorgbio.2017.12.011
SP  - 155
EP  - 162
ER  - 

@article{
author = "Edeler, David and Arlt, Sören and Petković, Vladana and Ludwig, Gerd and Drača, Dijana and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Kaluđerović, Goran N.",
year = "2018",
abstract = "SBA-15 (Santa Barbara Amorphous 15) mesoporous silica and its functionalized form (with 3-mercaptopropyltriethoxysilane) SBA-15~SH were used as carriers for [Ru(η6-p-cymene)Cl2{Ph2P(CH2)3SPh-κP}] complex, denoted as [Ru]. Prepared mesoporous silica nanomaterials were characterized by traditional methods. Materials without [Ru] complex did not show any cytotoxic activity against melanoma B16 and B16-F10 cell lines. On the contrary, materials containing [Ru] such as SBA-15|[Ru] and SBA-15~SH|[Ru], exhibited very high activity against tested tumor cell lines, moreover with similar inhibitory potential. According to the loaded amount of the [Ru] in SBA-15|[Ru] and SBA-15~SH|[Ru] the IC50 values are 1-2μM depending on the test used, thus in comparison to [Ru] alone the activity of nanomaterials containing [Ru] are elevated 3-6 times in vitro. However, the mechanism of apoptosis induction differs for these two mesoporous silica. Unlike reference [Ru] compound and SBA-15~SH|[Ru], SBA-15|[Ru] induces high caspase activation. Discrepancy in mechanism of drugs action at intracellular level points towards an influence of functionalization as well as availability of the drug. Moreover, both SBA-15|[Ru] and SBA-15~SH|[Ru] similarly to [Ru] are declining autophagy in B16 cell line.",
journal = "Journal of Inorganic Biochemistry",
title = "Delivery of [Ru(η6-p-cymene)Cl2{Ph2P(CH2)3SPh-κP}] using unfunctionalized and mercapto functionalized SBA-15 mesoporous silica: Preparation, characterization and in vitro study.",
volume = "180",
doi = "10.1016/j.jinorgbio.2017.12.011",
pages = "155-162"
}

Edeler, D., Arlt, S., Petković, V., Ludwig, G., Drača, D., Maksimović-Ivanić, D., Mijatović, S.,& Kaluđerović, G. N.. (2018). Delivery of [Ru(η6-p-cymene)Cl2{Ph2P(CH2)3SPh-κP}] using unfunctionalized and mercapto functionalized SBA-15 mesoporous silica: Preparation, characterization and in vitro study.. in Journal of Inorganic Biochemistry, 180, 155-162.
https://doi.org/10.1016/j.jinorgbio.2017.12.011

Edeler D, Arlt S, Petković V, Ludwig G, Drača D, Maksimović-Ivanić D, Mijatović S, Kaluđerović GN. Delivery of [Ru(η6-p-cymene)Cl2{Ph2P(CH2)3SPh-κP}] using unfunctionalized and mercapto functionalized SBA-15 mesoporous silica: Preparation, characterization and in vitro study.. in Journal of Inorganic Biochemistry. 2018;180:155-162.
doi:10.1016/j.jinorgbio.2017.12.011 .

Edeler, David, Arlt, Sören, Petković, Vladana, Ludwig, Gerd, Drača, Dijana, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Kaluđerović, Goran N., "Delivery of [Ru(η6-p-cymene)Cl2{Ph2P(CH2)3SPh-κP}] using unfunctionalized and mercapto functionalized SBA-15 mesoporous silica: Preparation, characterization and in vitro study." in Journal of Inorganic Biochemistry, 180 (2018):155-162,
https://doi.org/10.1016/j.jinorgbio.2017.12.011 . .

TY  - JOUR
AU  - Ludwig, Gerd
AU  - Mojić, Marija
AU  - Bulatović, Mirna
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Steinborn, Dirk
AU  - Kaluđerović, Goran N
PY  - 2016
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3827
AB  - In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1-4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5-8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1-4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug's tumoricidal action on 8505C cell line.
PB  - Sharjah: Bentham Science Publishers
T2  - Anti-Cancer Agents in Medicinal Chemistry
T1  - Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes
IS  - 11
VL  - 16
DO  - 10.2174/1871520615666151029100749
SP  - 1455
EP  - 1460
ER  - 

@article{
author = "Ludwig, Gerd and Mojić, Marija and Bulatović, Mirna and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Steinborn, Dirk and Kaluđerović, Goran N",
year = "2016",
abstract = "In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1-4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5-8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1-4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug's tumoricidal action on 8505C cell line.",
publisher = "Sharjah: Bentham Science Publishers",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
title = "Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes",
number = "11",
volume = "16",
doi = "10.2174/1871520615666151029100749",
pages = "1455-1460"
}

Ludwig, G., Mojić, M., Bulatović, M., Mijatović, S., Maksimović-Ivanić, D., Steinborn, D.,& Kaluđerović, G. N.. (2016). Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes. in Anti-Cancer Agents in Medicinal Chemistry
Sharjah: Bentham Science Publishers., 16(11), 1455-1460.
https://doi.org/10.2174/1871520615666151029100749

Ludwig G, Mojić M, Bulatović M, Mijatović S, Maksimović-Ivanić D, Steinborn D, Kaluđerović GN. Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes. in Anti-Cancer Agents in Medicinal Chemistry. 2016;16(11):1455-1460.
doi:10.2174/1871520615666151029100749 .

Ludwig, Gerd, Mojić, Marija, Bulatović, Mirna, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Steinborn, Dirk, Kaluđerović, Goran N, "Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes" in Anti-Cancer Agents in Medicinal Chemistry, 16, no. 11 (2016):1455-1460,
https://doi.org/10.2174/1871520615666151029100749 . .

TY  - JOUR
AU  - Ludwig, Gerd
AU  - Randelovic, Ivan
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Bulatović, Mirna Z.
AU  - Miljković, Đorđe
AU  - Korb, Marcus
AU  - Lang, Heinrich
AU  - Steinborn, Dirk
AU  - Kaluđerović, Goran N.
PY  - 2014
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2193
AB  - Iridium(III) complexes of the type
   {[}Ir(eta(5)-C5Me5)Cl-2\{Ph2PCH2-CH2CH2S(O)(x)Ph-kappa P\}] (x=0-2; 1-3)
   and {[}Ir(eta(5)-C5Me5)Cl\{Ph2PCH2-CH2CH2S(O)(x)Ph-kappa P,kappa
   S\}]{[}PF6] (x=0-1; 4 and 5) with 3-(diphenyl-phosphino)propyl phenyl
   sulfide, sulfoxide, and sulfone ligands Ph2PCH2CH2CH2S(O)(x)Ph were
   designed, synthesized, and characterized fully, including X-ray
   diffraction analyses for complexes 3 and 4. In vitro studies against
   human thyroid carcinoma (8505C), submandibular carcinoma (A253), breast
   adenocarcinoma (MCF-7), colon adenocarcinoma (SW480), and melano-ma
   (518A2) cell lines provided evidence for the high biological potential
   of the neutral and cationic iridium(III) complexes. Neutral iridium(III)
   complex 5 proved to be the most active, with IC50 values up to about 0.1
   mu m, representing activities of up to one order of magnitude higher
   than cisplatin. Using 8505C cells, apoptosis was shown to be the main
   mechanism through which complex 5 exerts its tumoricidal action. The
   described iridium(III) complexes represent potential leads in the search
   for novel metal-based anticancer agents.
T2  - Chemmedchem
T1  - Anticancer Potential of
 (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing
 kappa P and kappa P,kappa S-Coordinated Ph2PCH2CH2CH2S(O)(x)Ph (x=0-2)
 Ligands
IS  - 7
VL  - 9
DO  - 10.1002/cmdc.201300479
SP  - 1586
EP  - 1593
ER  - 

@article{
author = "Ludwig, Gerd and Randelovic, Ivan and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Bulatović, Mirna Z. and Miljković, Đorđe and Korb, Marcus and Lang, Heinrich and Steinborn, Dirk and Kaluđerović, Goran N.",
year = "2014",
abstract = "Iridium(III) complexes of the type
   {[}Ir(eta(5)-C5Me5)Cl-2\{Ph2PCH2-CH2CH2S(O)(x)Ph-kappa P\}] (x=0-2; 1-3)
   and {[}Ir(eta(5)-C5Me5)Cl\{Ph2PCH2-CH2CH2S(O)(x)Ph-kappa P,kappa
   S\}]{[}PF6] (x=0-1; 4 and 5) with 3-(diphenyl-phosphino)propyl phenyl
   sulfide, sulfoxide, and sulfone ligands Ph2PCH2CH2CH2S(O)(x)Ph were
   designed, synthesized, and characterized fully, including X-ray
   diffraction analyses for complexes 3 and 4. In vitro studies against
   human thyroid carcinoma (8505C), submandibular carcinoma (A253), breast
   adenocarcinoma (MCF-7), colon adenocarcinoma (SW480), and melano-ma
   (518A2) cell lines provided evidence for the high biological potential
   of the neutral and cationic iridium(III) complexes. Neutral iridium(III)
   complex 5 proved to be the most active, with IC50 values up to about 0.1
   mu m, representing activities of up to one order of magnitude higher
   than cisplatin. Using 8505C cells, apoptosis was shown to be the main
   mechanism through which complex 5 exerts its tumoricidal action. The
   described iridium(III) complexes represent potential leads in the search
   for novel metal-based anticancer agents.",
journal = "Chemmedchem",
title = "Anticancer Potential of
 (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing
 kappa P and kappa P,kappa S-Coordinated Ph2PCH2CH2CH2S(O)(x)Ph (x=0-2)
 Ligands",
number = "7",
volume = "9",
doi = "10.1002/cmdc.201300479",
pages = "1586-1593"
}

Ludwig, G., Randelovic, I., Maksimović-Ivanić, D., Mijatović, S., Bulatović, M. Z., Miljković, Đ., Korb, M., Lang, H., Steinborn, D.,& Kaluđerović, G. N.. (2014). Anticancer Potential of
 (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing
 kappa P and kappa P,kappa S-Coordinated Ph2PCH2CH2CH2S(O)(x)Ph (x=0-2)
 Ligands. in Chemmedchem, 9(7), 1586-1593.
https://doi.org/10.1002/cmdc.201300479

Ludwig G, Randelovic I, Maksimović-Ivanić D, Mijatović S, Bulatović MZ, Miljković Đ, Korb M, Lang H, Steinborn D, Kaluđerović GN. Anticancer Potential of
 (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing
 kappa P and kappa P,kappa S-Coordinated Ph2PCH2CH2CH2S(O)(x)Ph (x=0-2)
 Ligands. in Chemmedchem. 2014;9(7):1586-1593.
doi:10.1002/cmdc.201300479 .

Ludwig, Gerd, Randelovic, Ivan, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Bulatović, Mirna Z., Miljković, Đorđe, Korb, Marcus, Lang, Heinrich, Steinborn, Dirk, Kaluđerović, Goran N., "Anticancer Potential of
 (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing
 kappa P and kappa P,kappa S-Coordinated Ph2PCH2CH2CH2S(O)(x)Ph (x=0-2)
 Ligands" in Chemmedchem, 9, no. 7 (2014):1586-1593,
https://doi.org/10.1002/cmdc.201300479 . .

TY  - JOUR
AU  - Ludwig, Gerd
AU  - Mijatović, Sanja
AU  - Ranđelović, Ivan
AU  - Bulatović, Mirna Z.
AU  - Miljković, Đorđe
AU  - Maksimović-Ivanić, Danijela
AU  - Korb, Marcus
AU  - Lang, Heinrich
AU  - Steinborn, Dirk
AU  - Kaluđerović, Goran N.
PY  - 2013
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/948
AB  - Neutral iridium(III) complexes of the type [Ir(eta(5)-C5Me5)Cl-2{Ph2PCH2S(O)(x)Ph-kappa P}] (1-3) with diphenylphosphino-functionalized methyl phenyl sulfides, sulfoxides, and sulfones Ph2PCH2S(O)(x)Ph (x = 0, L1; 1, 12; 2, L3) and the cationic complex [Ir(eta(5)-C5Me5)Cl(Ph2PCH2SPh-kappa P,kappa S}][PF6] (4) were synthesized and fully characterized analytically and spectroscopically. Furthermore, the structure of 2 was determined by X-ray diffraction analysis. The biological potential of the neutral and cationic iridium(III) complexes was tested in vitro against the cell lines 8505C, A253, MCF-7, SW480 and 518A2. Complex [Ir(eta(5)-C5Me5)Cl-2{Ph2PCH2S(O)Ph-kappa P}] (2), with ligand L2 kappa P coordinated containing a pendent sulfinyl group, is the most active one (IC50 values of about 3 mu M), thus, with activities comparable to cisplatin. Complex 2 proved to have an even a higher antiproliferative activity than cisplatin against 8505C and SW480 cell lines, used as a model system of highly anaplastic cancers with low sensitivity to conventional chemotherapeutics such as cisplatin. Additional experiments demonstrated that apoptosis and autophagic cell death contribute to the drug's tumoricidal action. (C) 2013 Elsevier Masson SAS. All rights reserved.
T2  - European Journal of Medicinal Chemistry
T1  - Biological activity of neutral and cationic iridium(III) complexes with kappa P and kappa P,kappa S coordinated Ph2PCH2S(O)(x)Ph (x=0-2) ligands
IS  - null
VL  - 69
SP  - 33
EP  - 222
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_948
ER  - 

@article{
author = "Ludwig, Gerd and Mijatović, Sanja and Ranđelović, Ivan and Bulatović, Mirna Z. and Miljković, Đorđe and Maksimović-Ivanić, Danijela and Korb, Marcus and Lang, Heinrich and Steinborn, Dirk and Kaluđerović, Goran N.",
year = "2013",
abstract = "Neutral iridium(III) complexes of the type [Ir(eta(5)-C5Me5)Cl-2{Ph2PCH2S(O)(x)Ph-kappa P}] (1-3) with diphenylphosphino-functionalized methyl phenyl sulfides, sulfoxides, and sulfones Ph2PCH2S(O)(x)Ph (x = 0, L1; 1, 12; 2, L3) and the cationic complex [Ir(eta(5)-C5Me5)Cl(Ph2PCH2SPh-kappa P,kappa S}][PF6] (4) were synthesized and fully characterized analytically and spectroscopically. Furthermore, the structure of 2 was determined by X-ray diffraction analysis. The biological potential of the neutral and cationic iridium(III) complexes was tested in vitro against the cell lines 8505C, A253, MCF-7, SW480 and 518A2. Complex [Ir(eta(5)-C5Me5)Cl-2{Ph2PCH2S(O)Ph-kappa P}] (2), with ligand L2 kappa P coordinated containing a pendent sulfinyl group, is the most active one (IC50 values of about 3 mu M), thus, with activities comparable to cisplatin. Complex 2 proved to have an even a higher antiproliferative activity than cisplatin against 8505C and SW480 cell lines, used as a model system of highly anaplastic cancers with low sensitivity to conventional chemotherapeutics such as cisplatin. Additional experiments demonstrated that apoptosis and autophagic cell death contribute to the drug's tumoricidal action. (C) 2013 Elsevier Masson SAS. All rights reserved.",
journal = "European Journal of Medicinal Chemistry",
title = "Biological activity of neutral and cationic iridium(III) complexes with kappa P and kappa P,kappa S coordinated Ph2PCH2S(O)(x)Ph (x=0-2) ligands",
number = "null",
volume = "69",
pages = "33-222",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_948"
}

Ludwig, G., Mijatović, S., Ranđelović, I., Bulatović, M. Z., Miljković, Đ., Maksimović-Ivanić, D., Korb, M., Lang, H., Steinborn, D.,& Kaluđerović, G. N.. (2013). Biological activity of neutral and cationic iridium(III) complexes with kappa P and kappa P,kappa S coordinated Ph2PCH2S(O)(x)Ph (x=0-2) ligands. in European Journal of Medicinal Chemistry, 69(null), 33-222.
https://hdl.handle.net/21.15107/rcub_ibiss_948

Ludwig G, Mijatović S, Ranđelović I, Bulatović MZ, Miljković Đ, Maksimović-Ivanić D, Korb M, Lang H, Steinborn D, Kaluđerović GN. Biological activity of neutral and cationic iridium(III) complexes with kappa P and kappa P,kappa S coordinated Ph2PCH2S(O)(x)Ph (x=0-2) ligands. in European Journal of Medicinal Chemistry. 2013;69(null):33-222.
https://hdl.handle.net/21.15107/rcub_ibiss_948 .

Ludwig, Gerd, Mijatović, Sanja, Ranđelović, Ivan, Bulatović, Mirna Z., Miljković, Đorđe, Maksimović-Ivanić, Danijela, Korb, Marcus, Lang, Heinrich, Steinborn, Dirk, Kaluđerović, Goran N., "Biological activity of neutral and cationic iridium(III) complexes with kappa P and kappa P,kappa S coordinated Ph2PCH2S(O)(x)Ph (x=0-2) ligands" in European Journal of Medicinal Chemistry, 69, no. null (2013):33-222,
https://hdl.handle.net/21.15107/rcub_ibiss_948 .